Key Highlights
- Artelo Biosciences (ARTL) shares skyrocketed more than 40% during pre-market hours on March 18, 2026
- The rally followed news of a partnership with Belfast Health and Social Care Trust for a fully-funded glaucoma clinical trial
- ART27.13, the company’s peripherally selective synthetic cannabinoid candidate, will be evaluated in patients suffering from glaucoma or ocular hypertension
- Financial backing is provided by Glaucoma UK alongside the HSC R&D Division, with patient recruitment anticipated to begin in Q2 2026
- This development comes shortly after a 1-for-3 reverse stock split that became effective on March 10, 2026
Shares of Artelo Biosciences (ARTL) exploded higher by over 40% during Wednesday’s pre-market session following the company’s disclosure of a fully-funded clinical investigation for its synthetic cannabinoid therapy ART27.13 targeting glaucoma.
Artelo Biosciences, Inc., ARTL
The investigator-led clinical study was established through a partnership with the Belfast Health and Social Care Trust (BHSCT). Financial support for the research comes from Glaucoma UK in conjunction with the HSC R&D Division.
This pilot investigation will employ a randomized, cross-over design. The primary objective is to evaluate ART27.13’s ability to reduce intraocular pressure (IOP) among individuals diagnosed with glaucoma or ocular hypertension.
ART27.13 functions as a peripherally selective synthetic cannabinoid receptor agonist. This mechanism allows it to activate cannabinoid receptors located in peripheral tissues — such as those within the eye — while avoiding central nervous system effects.
Current therapeutic options for glaucoma predominantly consist of topical eye drop formulations, which frequently face challenges related to patient compliance and sustained efficacy over time. According to Artelo, ART27.13’s unique design could potentially sidestep the psychoactive adverse effects that have historically constrained cannabinoid-based ocular therapies.
Regulatory clearance for the study protocol has been obtained from both an ethics review board and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). Initial patient enrollment is projected to commence during Q2 2026.
Professor Augusto Azuara-Blanco will serve as the principal investigator. He holds a position as clinical professor of ophthalmology at Queen’s University Belfast and maintains an established reputation as a leading authority in glaucoma research.
Glaucoma impacts over 80 million individuals globally and ranks among the primary causes of permanent vision loss. Increased IOP represents the principal modifiable risk factor in disease advancement.
Capital-Efficient Development Approach
Chief Executive Officer Greg Gorgas characterized the arrangement as an integral component of the company’s resource-conscious development framework. The organization is allowing external funding sources to sponsor this investigation while maintaining its internal resources concentrated on ART27.13’s core indication — anorexia associated with cancer.
“This collaboration exemplifies our capital-efficient development strategy,” Gorgas said in the announcement. “Each study contributes to a growing body of evidence that could enhance the value of ART27.13.”
Under the terms of this arrangement, Artelo will furnish ART27.13 capsules serving as the Investigational Medicinal Product for the clinical trial. All other financial responsibilities remain with the study’s external funding partners.
Financial Background
The dramatic pre-market rally occurs within the context of significant financial headwinds. Artelo disclosed a net loss totaling $12.9 million for the fiscal year concluded December 31, 2025, representing an increase from the $9.8 million loss recorded in the preceding year.
Cash reserves and investments amounted to merely $0.6 million at year-end. InvestingPro’s Financial Health Score designates the company’s position as “WEAK.”
The company executed a 1-for-3 reverse stock split on March 10, 2026. Common shares outstanding decreased from roughly 2.1 million to 708,323 shares as a result of this corporate restructuring.
Before Wednesday’s surge, ARTL had tumbled 67% during the preceding six-month period. The shares were changing hands at $4.85 with a market capitalization of approximately $3.47 million ahead of the pre-market rally.
The glaucoma research initiative marks Artelo’s inaugural venture into ophthalmology and its first externally-sponsored clinical partnership.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
